Trial Profile
A prospective, open-label, multi-center, post marketing study to evaluate safety and efficacy of fixed dose combination (FDC) tablets of arterolane maleate and piperaquine phosphate (PQP) in Indian patients with acute uncomplicated falciparum malaria.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Arterolane/piperaquine (Primary)
- Indications Falciparum malaria
- Focus Therapeutic Use
- Sponsors Ranbaxy Laboratories
- 19 Mar 2014 Status changed from recruiting to completed, as per Clinical Trials Registry - India record.
- 25 Jan 2014 New trial record